Tanios Bekaii-Saab, MD is the David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research I at the Mayo Clinic College of Medicine and Science. He is the Chair for Hematology and Medical Oncology for the Division of Hematology/Oncology at the Mayo Clinic in Phoenix, Arizona, USA. He is the leader of the Gastrointestinal Cancer Program for the Enterprise-wide Mayo Clinic Cancer Center. Dr. Bekaii-Saab is currently the co-leader of the Hepatobiliary Cancer Sub-Committee of the Alliance for Clinical Trials in Oncology and the Co-Chair for the National Cancer Institute’s Hepatobiliary Task Force. 

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.

Dr. Bekaii-Saab conducts clinical and translational research focused on developing anticancer agents for patients with gastrointestinal cancers. His research led to the launch of several phase II and III clinical trials, many yielding FDA approvals and the incorporation of novel agents into the NCCN and ESMO guidelines.

Dr. Bekaii-Saab served as a reviewer for many high impact journals and sits on the editorial board of the prestigious Journal of the National Cancer Institute.  Dr. Bekaii-Saab has authored or co-authored more than 500 peer reviewed publications, abstracts, and book chapters, including papers in such journals as New England Journal of Medicine, Lancet, Nature Medicine, Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.